Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03597399 · ClinicalTrials.gov registry record
A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US
A clinical trial, sponsored by Spark Therapeutics.
- Completed
- Registry status
- 87
- Enrollment target
NCT03597399 is a clinical trial that has completed, run by Spark Therapeutics. The registered enrollment target is 87 participants.
The verdict
NCT03597399 has completed, sponsored by Spark Therapeutics.
- COMPLETED
- Registry status
- 87 participants
- Enrollment target
Study Summary
The objective of this study is to collect long-term safety information (i.e., for 5 years after treatment) associated with voretigene neparvovec-rzyl (vector and/or transgene), its subretinal injection procedure, the concomitant use of corticosteroids, or a combination of these procedures and products. The enrollment period will last for two years from the first treatment following product approval (through 31March2020) and include a minimum of 40 patients.
Interventions
- BIOLOGICAL AAV2-hRPE65v2,voretigene neparvovec-rzyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2019-01-10 |
| Est. Completion | 2025-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03597399
The ClinicalTrials.gov registry entry for NCT03597399 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spark Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AAV2-hRPE65v2,voretigene neparvovec-rzyl is the first listed.
NCT03597399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03597399 about?
NCT03597399 is a clinical study titled "A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US". The objective of this study is to collect long-term safety information (i.e., for 5 years after treatment) associated with voretigene neparvovec-rzyl (vector and/or transgene), its subretinal injection procedure, the concomitant use of corticosteroids, or a combination of these procedures and produc...
What is the current status of trial NCT03597399?
This trial is currently completed. The enrollment target is 87 participants. The study started on 2019-01-10. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT03597399?
The interventions under investigation include: AAV2-hRPE65v2,voretigene neparvovec-rzyl (BIOLOGICAL).
Who is sponsoring clinical trial NCT03597399?
This trial is sponsored by Spark Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.